- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04283552
Gated and Non-Gated Dynamic PET/CT Imaging
February 23, 2024 updated by: Washington University School of Medicine
An Exploration of Gated and Non-Gated Dynamic PET/CT Imaging
The goal of this study is to see how the images collected during the first hour compare with the routine images collected as part of the clinical scan.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Richard L Wahl, M.D.
- Phone Number: 314-362-7100
- Email: rwahl@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Sub-Investigator:
- Tyler J Fraum, M.D.
-
Contact:
- Richard L Wahl, M.D.
- Phone Number: 314-362-7100
- Email: rwahl@wustl.edu
-
Principal Investigator:
- Richard L Wahl, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria Main Cohort:
- 18 years of age or older
- Scheduled to undergo a clinical PET/CT scan with any clinically prescribed radiotracer for known or suspected malignancy (pathologic confirmation not required)
- Able to provide informed consent
Inclusion Criteria Repeatability Cohort:
- 18 years of age or older
- Scheduled to undergo a clinical PET/CT FDG or 68Ga- DOTA-0-Tyr3-Octreotate (DOTATATE) for known or suspected malignancy (pathologic confirmation not required)
- Able to provide informed consent
Exclusion Criteria:
-Younger than 18 years of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dynamic PET Imaging
|
-Will take approximately 60 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of rapid, whole-body dynamic PET imaging as measured by number of participants who successfully complete the study imaging component
Time Frame: Completion of imaging for all participants enrolled in the study (estimated to be 4 years)
|
-Successful completion of the study imaging component will be defined as: (1) patient remains on scanner for the full dynamic phase of PET imaging prior to the standard of care PET/CT and (2) automated scanner software is able to successfully generate valid parametric maps (requires at least three consecutive whole-body PET acquisitions without substantial motion between acquisitions).
|
Completion of imaging for all participants enrolled in the study (estimated to be 4 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative impacts of data motion correction (OncoFreeze) as measured by semi-quantitative standardized uptake value (SUV) metrics
Time Frame: At the time of scan (Day 1)
|
|
At the time of scan (Day 1)
|
Clinical impacts of data motion correction (OncoFreeze) as measured by number of detectable lesions
Time Frame: At the time of scan (Day 1)
|
|
At the time of scan (Day 1)
|
Repeatability of dynamic imaging as measured by calculating the measurement agreement in semi-quantitative PET metrics between test and retest dynamic images
Time Frame: Day 1 and approximately 1 week later
|
-Imaging metric agreement will be measured using Bland-Altman analysis.
Groupwise differences between imaging time-points will also be assessed using t-tests or Mann-Whitney U tests, depending on normality.
|
Day 1 and approximately 1 week later
|
Metabolic rate of images
Time Frame: At the time of scan (Day 1)
|
-Will help to determine the optimal post-injection time period for dynamic PET imaging for Patlak analysis.
|
At the time of scan (Day 1)
|
Volume of distribution (intercept) images
Time Frame: At the time of scan (Day 1)
|
-Will help to determine the optimal post-injection time period for dynamic PET imaging for Patlak analysis.
|
At the time of scan (Day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Richard L Wahl, M.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2020
Primary Completion (Actual)
April 10, 2023
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
February 20, 2020
First Submitted That Met QC Criteria
February 24, 2020
First Posted (Actual)
February 25, 2020
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 23, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 201910076
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The investigators may share your images with other researchers.
They may be doing research in areas similar to this research or in other unrelated areas.
These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research.
The investigators may also share your research data with large data repositories (a repository is a database of information) for broad sharing with the research community.
If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.
IPD Sharing Time Frame
Beginning 3 months and ending 10 years following article publication.
IPD Sharing Access Criteria
Proposals should be directly submitted to rwahl@wustl.edu.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dynamic PET/CT Imaging
-
University of CincinnatiNational Cancer Institute (NCI); Ohio Third FrontierActive, not recruitingPET/CT ImagingUnited States
-
University of CincinnatiOhio Third FrontierActive, not recruitingNew-generation Digital PET/CT ImagingUnited States
-
University Hospital Inselspital, BerneRecruiting
-
Kurume UniversityUnknownTo Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT ImagingJapan
-
Washington University School of MedicineNational Cancer Institute (NCI)Terminated
-
Sir Mortimer B. Davis - Jewish General HospitalEnrolling by invitation
-
Assiut UniversityUnknown
-
Royal Marsden NHS Foundation TrustCity, University of LondonUnknownFDG PET/CT | Skeletal ScintigraphyUnited Kingdom
-
GE HealthcareTerminatedIndication for a PET CT ExamUnited States
-
University of CincinnatiActive, not recruiting
Clinical Trials on Dynamic PET/CT Imaging
-
Maastricht Radiation OncologyMaastricht University Medical CenterTerminatedCerebral Astrocytoma, High GradeNetherlands
-
Gert MeijerM.D. Anderson Cancer CenterCompletedEsophageal CancerUnited States, Netherlands
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversitySun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical...Not yet recruitingEsophageal Squamous Cell Carcinoma | Benign Lymph Node Neoplasm | Malignant Lymph Node Neoplasm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingOvarian Carcinoma | Malignant Ovarian NeoplasmUnited States
-
GE HealthcareLaboratory Corporation of AmericaNot yet recruiting
-
Aarhus University HospitalCompletedPositron-Emission TomographyDenmark
-
Ontario Clinical Oncology Group (OCOG)Cancer Care OntarioActive, not recruitingMuscle-invasive Bladder CancerCanada
-
Weill Medical College of Cornell UniversityWithdrawnHead and Neck CancerUnited States
-
Rambam Health Care CampusUnknown